Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eileen Dolan

Showing results (61-70 of 188) with videos related to

Pageof 19
Sort By:
Breast Cancer Research and Treatment|November 29, 2017
Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test resultsDavid J Press, Abiola Ibraheem, M Eileen Dolan, et al.
DNA Repair|May 9, 2007
Role of MGMT in protecting against cyclophosphamide-induced toxicity in cells and animalsRyan J Hansen, Susan M Ludeman, Sari J Paikoff, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2018
Genetic and Modifiable Risk Factors Contributing to Cisplatin-induced ToxicitiesMatthew R Trendowski, Omar El Charif, Paul C Dinh, et al.
Pharmacogenetics|July 2, 2003
Characterization of multiple promoters in the human carboxylesterase 2 geneMichael H Wu, Peixian Chen, Benjamin F Remo, et al.
Frontiers in Pharmacology|September 11, 2025
Comparison of associations suggests mainly distinct pools of genetic risk factors contribute to cisplatin-induced hearing loss and hearing difficulty in the general populationMohammad Shahbazi, Heather E Wheeler, Xindi Zhang, et al.
The Pharmacogenomics Journal|May 26, 2018
Integration of genetic and functional genomics data to uncover chemotherapeutic induced cytotoxicityRuowang Li, Dokyoon Kim, Heather E Wheeler, et al.
Scientific Reports|November 14, 2024
Comparison of GWAS results between de novo tinnitus and cancer treatment-related tinnitus suggests distinctive roles for genetic risk factorsMohammad Shahbazi, Heather E Wheeler, Gregory T Armstrong, et al.
Cancer Chemotherapy and Pharmacology|November 11, 2008
Role of copper transporters in resistance to platinating agentsCara A Rabik, Edward B Maryon, Kristen Kasza, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2005
Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanomaThomas F Gajewski, Jeffrey Sosman, Stanton L Gerson, et al.
Clinical Pharmacology and Therapeutics|March 4, 2025
A National Study Among Diverse US Populations of Exposure to Prescription Medications with Evidence-Based Pharmacogenomic InformationLoren Saulsberry, Jacob C Jameson, Robert D Gibbons, et al.
Pageof 19

Showing results (61-70 of 188) with videos related to

Sort By:
Pageof 19
Breast Cancer Research and Treatment|November 29, 2017
Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test resultsDavid J Press, Abiola Ibraheem, M Eileen Dolan, et al.
DNA Repair|May 9, 2007
Role of MGMT in protecting against cyclophosphamide-induced toxicity in cells and animalsRyan J Hansen, Susan M Ludeman, Sari J Paikoff, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2018
Genetic and Modifiable Risk Factors Contributing to Cisplatin-induced ToxicitiesMatthew R Trendowski, Omar El Charif, Paul C Dinh, et al.
Pharmacogenetics|July 2, 2003
Characterization of multiple promoters in the human carboxylesterase 2 geneMichael H Wu, Peixian Chen, Benjamin F Remo, et al.
Frontiers in Pharmacology|September 11, 2025
Comparison of associations suggests mainly distinct pools of genetic risk factors contribute to cisplatin-induced hearing loss and hearing difficulty in the general populationMohammad Shahbazi, Heather E Wheeler, Xindi Zhang, et al.
The Pharmacogenomics Journal|May 26, 2018
Integration of genetic and functional genomics data to uncover chemotherapeutic induced cytotoxicityRuowang Li, Dokyoon Kim, Heather E Wheeler, et al.
Scientific Reports|November 14, 2024
Comparison of GWAS results between de novo tinnitus and cancer treatment-related tinnitus suggests distinctive roles for genetic risk factorsMohammad Shahbazi, Heather E Wheeler, Gregory T Armstrong, et al.
Cancer Chemotherapy and Pharmacology|November 11, 2008
Role of copper transporters in resistance to platinating agentsCara A Rabik, Edward B Maryon, Kristen Kasza, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2005
Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanomaThomas F Gajewski, Jeffrey Sosman, Stanton L Gerson, et al.
Clinical Pharmacology and Therapeutics|March 4, 2025
A National Study Among Diverse US Populations of Exposure to Prescription Medications with Evidence-Based Pharmacogenomic InformationLoren Saulsberry, Jacob C Jameson, Robert D Gibbons, et al.
Pageof 19